About GenDx
GenDx is a company based in Utrecht (Netherlands) founded in 2005 was acquired by Eurobio scientific in August 2022. GenDx offers products and services including HLA Typing, Chimerism Monitoring, NGS KIR Typing, NGS MICA, MICB Typing, and Custom Lab Service. GenDx operates in a competitive market with competitors including Omniome, Tessera Therapeutics, HitGen, Phase Genomics and Hexagon Bio, among others.
- Headquarter Utrecht, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Eurobio scientific
& 1 more
-
Employee Count
Not available
-
Acquired by
Eurobio scientific
(Aug 17, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GenDx
GenDx offers a comprehensive portfolio of products and services, including HLA Typing, Chimerism Monitoring, NGS KIR Typing, NGS MICA, MICB Typing, and Custom Lab Service.
Provides gene typing for transplant compatibility and donor matching.
Tracks cell mixtures in patients post-transplantation for health monitoring.
Offers next-generation sequencing for killer cell immunoglobulin receptors.
Performs sequencing for major histocompatibility complex class I chain genes.
Delivers tailored diagnostic solutions for specific research needs.
Funding Insights of GenDx
Investors in GenDx
GenDx has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Eurobio scientific and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Locked | Locked | Locked | |
|
Provider of vitro diagnostic services and products
|
Locked | Locked | Locked |
Investor details for GenDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenDx
Investment portfolio details for GenDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GenDx
Detailed financials for GenDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gendx Comparisons
Peer comparison for GenDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GenDx
GenDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Omniome, Tessera Therapeutics, HitGen, Phase Genomics and Hexagon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
New genome engineering technology is provided for treating multiple diseases.
|
|
| Locked | Locked | Locked |
DNA-encoded libraries are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
Bioinformatics tools are provided for analyzing microbial genomic sequencing data.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
Detailed competitors of GenDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gendx
Complete news archive for GenDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenDx
GenDx was founded in 2005 and raised its 1st funding round 14 years after it was founded.
GenDx is headquartered in Utrecht, Netherlands.
GenDx was founded in 2005 in Utrecht, Netherlands, within the in vitro diagnostics sector. Products focused on HLA typing for transplant applications are developed and marketed, including reagents and kits for Sanger sequencing and next-generation sequencing. Analysis software for sequencing data is also provided, alongside educational services to support clinical and research use. Operations emphasize precision in transplant compatibility assessments.
GenDx's top competitors include Tessera Therapeutics, Novogene Corporation and Phase Genomics.
GenDx offers HLA Typing, Chimerism Monitoring, NGS KIR Typing, NGS MICA, MICB Typing, and Custom Lab Service.
GenDx has 2 investors. Key investors include Eurobio scientific, and Ampersand Capital Partners.